Suppr超能文献

多重耐药感染的传播导致肝硬化患者经验性抗生素治疗失败率上升:一项前瞻性调查。

The spread of multi drug resistant infections is leading to an increase in the empirical antibiotic treatment failure in cirrhosis: a prospective survey.

作者信息

Merli Manuela, Lucidi Cristina, Di Gregorio Vincenza, Falcone Marco, Giannelli Valerio, Lattanzi Barbara, Giusto Michela, Ceccarelli Giancarlo, Farcomeni Alessio, Riggio Oliviero, Venditti Mario

机构信息

Gastroenterology, Department of Clinical Medicine, "Sapienza" University of Rome, Rome, Italy.

Department of Infectious disease, "Sapienza" University of Rome, Rome, Italy.

出版信息

PLoS One. 2015 May 21;10(5):e0127448. doi: 10.1371/journal.pone.0127448. eCollection 2015.

Abstract

BACKGROUND

The spread of multi-resistant infections represents a continuously growing problem in cirrhosis, particularly in patients in contact with the healthcare environment.

AIM

Our prospective study aimed to analyze epidemiology, prevalence and risk factors of multi-resistant infections, as well as the rate of failure of empirical antibiotic therapy in cirrhotic patients.

METHODS

All consecutive cirrhotic patients hospitalized between 2008 and 2013 with a microbiologically-documented infection (MDI) were enrolled. Infections were classified as Community-Acquired (CA), Hospital-Acquired (HA) and Healthcare-Associated (HCA). Bacteria were classified as Multidrug-Resistant (MDR) if resistant to at least three antimicrobial classes, Extensively-Drug-Resistant (XDR) if only sensitive to one/two classes and Pandrug-Resistant (PDR) if resistant to all classes.

RESULTS

One-hundred-twenty-four infections (15% CA, 52% HA, 33% HCA) were observed in 111 patients. Urinary tract infections, pneumonia and spontaneous bacterial peritonitis were the more frequent. Forty-seven percent of infections were caused by Gram-negative bacteria. Fifty-one percent of the isolates were multi-resistant to antibiotic therapy (76% MDR, 21% XDR, 3% PDR): the use of antibiotic prophylaxis (OR = 8.4; 95%CI = 1.03-76; P = 0,05) and current/recent contact with the healthcare-system (OR = 3.7; 95%CI = 1.05-13; P = 0.04) were selected as independent predictors. The failure of the empirical antibiotic therapy was progressively more frequent according to the degree of resistance. The therapy was inappropriate in the majority of HA and HCA infections.

CONCLUSIONS

Multi-resistant infections are increasing in hospitalized cirrhotic patients. A better knowledge of the epidemiological characteristics is important to improve the efficacy of empirical antibiotic therapy. The use of preventive measures aimed at reducing the spread of multi-resistant bacteria is also essential.

摘要

背景

多重耐药感染的传播在肝硬化患者中是一个持续增长的问题,尤其是在与医疗环境有接触的患者中。

目的

我们的前瞻性研究旨在分析肝硬化患者多重耐药感染的流行病学、患病率和危险因素,以及经验性抗生素治疗的失败率。

方法

纳入2008年至2013年间所有因微生物学确诊感染(MDI)而住院的连续性肝硬化患者。感染分为社区获得性(CA)、医院获得性(HA)和医疗保健相关(HCA)。如果细菌对至少三类抗菌药物耐药,则分类为多重耐药(MDR);如果仅对一/两类敏感,则为广泛耐药(XDR);如果对所有类抗菌药物均耐药,则为全耐药(PDR)。

结果

在111例患者中观察到124例感染(15%为CA,52%为HA,33%为HCA)。尿路感染、肺炎和自发性细菌性腹膜炎最为常见。47%的感染由革兰氏阴性菌引起。51%的分离株对抗生素治疗多重耐药(76%为MDR,21%为XDR,3%为PDR):抗生素预防的使用(OR = 8.4;95%CI = 1.03 - 76;P = 0.05)以及当前/近期与医疗系统的接触(OR = 3.7;95%CI = 1.05 - 13;P = 0.04)被选为独立预测因素。根据耐药程度,经验性抗生素治疗失败越来越频繁。在大多数HA和HCA感染中,治疗是不恰当的。

结论

住院肝硬化患者中的多重耐药感染正在增加。更好地了解流行病学特征对于提高经验性抗生素治疗的疗效很重要。采取旨在减少多重耐药菌传播的预防措施也至关重要。

相似文献

7
New antibiotic strategies in patients with cirrhosis and bacterial infection.肝硬化合并细菌感染患者的新型抗生素策略
Expert Rev Gastroenterol Hepatol. 2015;9(12):1495-500. doi: 10.1586/17474124.2015.1100075. Epub 2015 Oct 14.

引用本文的文献

4
Multidrug-resistant bacterial infections in the liver transplant setting.肝移植患者中的多重耐药菌感染。
Updates Surg. 2024 Nov;76(7):2521-2529. doi: 10.1007/s13304-024-01903-6. Epub 2024 Jun 25.

本文引用的文献

8
Cirrhotic patients are at risk for health care-associated bacterial infections.肝硬化患者存在与医疗保健相关的细菌感染风险。
Clin Gastroenterol Hepatol. 2010 Nov;8(11):979-85. doi: 10.1016/j.cgh.2010.06.024. Epub 2010 Aug 12.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验